- Home
- CMLS vs PIRS Comparison
CMLS vs PIRS Comparison
Compare CMLS & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMLS
- PIRS
- Stock Information
- Founded
- CMLS 2002
- PIRS 2001
- Country
- CMLS United States
- PIRS United States
- Employees
- CMLS N/A
- PIRS N/A
- Industry
- CMLS Broadcasting
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- CMLS Consumer Discretionary
- PIRS Health Care
- Exchange
- CMLS Nasdaq
- PIRS Nasdaq
- Market Cap
- CMLS 21.5M
- PIRS 22.4M
- IPO Year
- CMLS 1998
- PIRS N/A
- Fundamental
- Price
- CMLS $0.73
- PIRS $15.89
- Analyst Decision
- CMLS Hold
- PIRS
- Analyst Count
- CMLS 2
- PIRS 0
- Target Price
- CMLS N/A
- PIRS N/A
- AVG Volume (30 Days)
- CMLS 68.9K
- PIRS 37.6K
- Earning Date
- CMLS 11-01-2024
- PIRS 11-13-2024
- Dividend Yield
- CMLS N/A
- PIRS N/A
- EPS Growth
- CMLS N/A
- PIRS N/A
- EPS
- CMLS N/A
- PIRS N/A
- Revenue
- CMLS $829,801,000.00
- PIRS $1,352,000.00
- Revenue This Year
- CMLS N/A
- PIRS N/A
- Revenue Next Year
- CMLS N/A
- PIRS N/A
- P/E Ratio
- CMLS N/A
- PIRS N/A
- Revenue Growth
- CMLS N/A
- PIRS N/A
- 52 Week Low
- CMLS $0.69
- PIRS $6.20
- 52 Week High
- CMLS $5.51
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- CMLS 27.72
- PIRS 43.29
- Support Level
- CMLS $0.69
- PIRS $15.15
- Resistance Level
- CMLS $0.76
- PIRS $16.97
- Average True Range (ATR)
- CMLS 0.07
- PIRS 0.72
- MACD
- CMLS 0.00
- PIRS -0.08
- Stochastic Oscillator
- CMLS 12.95
- PIRS 30.75
About CMLS Cumulus Media Inc.
Cumulus Media Inc is an audio-first media company delivering content to over a quarter billion people every month wherever and whenever required. It is a radio broadcasting company combining high-quality local programming with iconic, nationally syndicated media, sports, and entertainment brands to deliver premium content choices to its customers and radio stations affiliated with Westwood One network and numerous digital channels. The company's revenue is derived mainly from the sale of local, regional, and national advertising which is broadcast on its radio stations.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.